AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

The inter partes review (IPR) process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

10 February 2026 Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.

Americas

Novartis takes aim at Tafinlar generic in latest suit

9 February 2026 The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

More features

Novo Nordisk takes on Hims & Hers after $49 pill ‘turnaround’

Novartis takes aim at Tafinlar generic in latest suit

Semaglutide patent battle heats up with new blow for Novo in India

Wilson Sonsini senior counsel moves to a rival firm

AstraZeneca partners with Chinese firm ahead of next obesity race

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Nine-partner litigation team leaves Winston & Strawn

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

AIPPI 2018: Eli Lilly talks IPRs and biosimilar litigation

More on this story

Editor's picks

Editor's picks

More features